ZBH Earnings Date: Nov 4, 2026 (Estimated) — Zimmer Biomet Holdings, Inc.
NYSE · Healthcare · Medical Devices
Updated
When is ZBH's next earnings date?
Zimmer Biomet Holdings, Inc. (ZBH) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.88 on revenue of $2.04B.
How did ZBH do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Zimmer Biomet Holdings, Inc. posted EPS of $2.07 versus the $2.01 estimate, a beat of 3.0%. Revenue was $2.18B against a $2.13B estimate. The stock's 1-day post-earnings move was +2.4%.
How much does ZBH stock move after earnings?
ZBH beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.6% (up or down) in the day after earnings.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 2.01 | 2.07 | +2.99% | $2.18B | ✅ Beat | +2.45% | +1.48% | +3.85% |
| 2026-04-28 | Q1 2026 | 1.86 | 2.09 | +12.37% | $2.09B | ✅ Beat | -10.58% | -10.72% | -10.84% |
| 2026-02-10 | Q4 2025 | 2.39 | 2.42 | +1.26% | $2.24B | ✅ Beat | +1.86% | +8.27% | +4.46% |
| 2025-11-05 | Q3 2025 | 1.87 | 1.90 | +1.60% | $2.00B | ✅ Beat | -15.14% | -14.22% | -9.71% |
| 2025-08-07 | Q2 2025 | 1.98 | 2.07 | +4.55% | $2.08B | ✅ Beat | +7.98% | +13.24% | +15.99% |
| 2025-05-05 | Q1 2025 | 1.77 | 1.81 | +2.26% | $1.91B | ✅ Beat | -11.62% | -7.00% | -10.28% |
| 2025-02-06 | Q4 2024 | 2.29 | 2.31 | +0.87% | $2.02B | ✅ Beat | -5.13% | -8.55% | -0.24% |
| 2024-10-30 | Q3 2024 | 1.73 | 1.74 | +0.58% | $1.82B | ✅ Beat | +5.71% | +4.85% | +7.84% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.98B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Knees | 41.9% | $828.9M | +0.4% | $839.2M | $792.9M | $826.0M | $792.4M |
| S E T | 29.6% | $586.0M | +6.4% | $489.4M | $470.5M | $550.6M | $541.5M |
| Hips | 28.5% | $562.7M | +5.0% | $519.9M | $495.8M | $536.1M | $506.2M |
By region
Q2 FY26 · $2.18B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 62.4% | $1.36B | +6.7% | $1.27B | $1.20B | $1.27B | $1.25B |
| E M E A | 22.0% | $478.5M | +2.4% | $437.7M | $443.1M | $467.5M | $417.0M |
| Asia Pacific | 15.6% | $339.5M | +1.0% | $312.5M | $261.7M | $336.1M | $330.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.